← Russell 3000 cross-section

AQST Aquestive Therapeutics, Inc.

Trailing twelve months to 2026-06-30 · as filed 2026-08-11, not restated
Healthcare

Scale

Market cap
$649m
Revenue TTM
$54m
Net income TTM
$-78m
Free cash flow
$-46m
Composite score
Sector rank
#2270

Valuation

P / E
EV / EBITDA
EV / sales
11.2
FCF yield
-7.08%
Earnings yield vs 10-yr
-16.77pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.73% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
-144.6%
EBITDA margin
-96.6%
ROE
138.2%
ROIC
Revenue growth
22.6%

Insider activity, last 90 days

Net open-market
$-0.44m
Buyers
0
Sellers
2

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

Under the terms of the license agreement with Zambon, an upfront payment was paid to Aquestive for the development and commercialization rights of Emylif in the EU, and Aquestive will be paid development and sales milestone payments and low double-digit royalties on net sales of the product in the EU. We will continue to manage business costs to prepare for a potential future decline in Suboxone ® revenue and other external factors affecting our business. …Aquestive Therapeutics, Inc., 10-Q, period ended 2026-06-30, filed 2026-08-11

Read the full passage →